The company continues to lead the generics and OTC segment, with No1 ranking and No7 in total market, according to own statements.
Ranbaxy group reported net sales of 1.6 Rupees (313 bln dollars) for the quarter ended March 31, down 4% from prior-year period.

For 2009, the company expects to achieve sales of approximately 70 billion Rupees (1.4 billion dollars).

Ranbaxy Laboratories, India’s largest drugmaker, bought in March 2006 96.7% stake in Terapia Cluj-Napoca from Advent International, paying 324 million dollars, in a bid to expand operations in European market.